Check how this study shows that TH1579 has the potential to improve ICI treatment by modulating immune checkpoint-related proteins and pathways.

“Mitotic MTH1 inhibitor TH1579 induces PD-L1 expression and inflammatory response through the cGAS-STING pathway” 🔵 Interesting research led by Thomas Helleday has been featured in #Oncogenesis. ▶️ Read the full open access article here: www.nature.com/articles/s41...

Check how this study suggests FABP4-mediated FA metabolism as a therapeutic target to counteract T cell senescence in adipocyte-rich TME, providing a novel immunotherapeutic strategy for Ovarian Cancer.

“Fatty acid uptake mediated by FABP4 promotes the formation of CD8+T cell senescence through lipid peroxidation in the adipocyte-rich microenvironment of Ovarian Cancer” 🔵 Weimin Deng ‘s research is now available to read in #Oncogenesis. ▶️ Read the full article here: www.nature.com/articles/s41...

Check how their study suggests that PHF2 acts as a candidate epigenetic tumour suppressor in HCC patients through the downregulation of SRXN1independent of Nrf2.

“The role of histone demethylase PHF2 as a tumour suppressor in hepatocellular carcinoma by regulating SRXN1” 🔵 Edward Kai-Hua Chow‘s latest research is now available to read in #Oncogenesis. ▶️ Read the full open access article here: www.nature.com/articles/s41...

Check how their results suggest that USP32 activates the RAF/MEK/ERK signaling pathway, which in turn promotes NSCLC cell proliferation, migration, and EMT progression through deubiquitination and stabilization of BAG3.

“USP32 facilitates non-small cell lung cancer progression via deubiquitinating BAG3 and activating RAF-MEK-ERK signaling pathway” 🔵 Interesting research led by Chunyan Liu has been featured in #Oncogenesis. ▶️ Read the full open access article here: www.nature.com/articles/s41...

Check how their study presents a novel model for understanding how genetic alterations in cytoskeletal genes can directly contribute to cancer development and drive cancer evolution and shows it can lead to the reactivation of cancer dormancy and tumour spread.

“Cytoskeleton reorganization induced by a novel K6-K14 keratin fusion promotes cancer stemness and cellular plasticity via cGAS-STING selection” 🔵 Jim Jinn-Chyuan Sheu‘s latest research is now available to read in #Oncogenesis. ▶️ Read the full article here: www.nature.com/articles/s41...

As an advocate for Oncogenesis, I regularly encourage colleagues to submit their latest studies to the journal and aim to promote Oncogenesis broadly through cancer research networks. We are very lucky to have him on the team at Oncogenesis! 🤝

I have served as Associate Editor of Oncogenesis for over 5 years and in this role, I continually strive to ensure we publish high quality research and new insights in these areas.

🧬 Meet One of Our Associate Editor: Philip Gregory As head of the Gene Regulation in Cancer laboratory at the Centre for Cancer Biology in Adelaide, my research focusses on understanding how epigenetic changes regulate cancer cell plasticity and contribute to metastasis and treatment resistance.

Check how their findings demonstrate that Rab37 governs macrophage phenotype and function by orchestrating OPN/STAT3 signalling, thereby reinforcing an immunosuppressive TME and promoting lung cancer progression.

“Rab37-mediated OPN secretion enriches SPP1+ macrophages through autocrine–paracrine signaling to drive lung tumor progression” 🔵 Yi-Ching Wang‘s latest research is now available to read in #Oncogenesis. ▶️ Read the full open access article here: www.nature.com/articles/s41...

Check how their study revealed a potential mechanism by which DAB2IP can act as a scaffold to promote the interaction between HIF-1α and STUB1, thus inducing HIF-1α ubiquitylation degradation and inhibiting glucose uptake in breast cancer cells under hypoxic conditions.

“DAB2IP inhibits glucose uptake by modulating HIF-1α ubiquitination under hypoxia in breast cancer” 🔵 Interesting research led by Jie Shen has been featured in #Oncogenesis. ▶️ Read the full open access article here: www.nature.com/articles/s41...

Check how their findings uncover a novel PRAS40/PGK1 regulatory axis that promotes CRC stemness and tumorigenesis through enhanced glycolysis, suggesting potential therapeutic strategies targeting this axis for CRC treatment.

“PRAS40 promotes colorectal cancer stemness by enhancing glycolysis through triggering PGK1 acetylation” 🔵Lin Huang‘s latest research is now available to read in #Oncogenesis. ▶️ Read the full open access article here: www.nature.com/articles/s41...

Check how demonstrated that combination therapies targeting PKC and PKC-independent signalling nodes, including PI3K/AKT activity, are required to improve responses in patients with metastatic uveal melanoma.

“PKC-independent PI3K signalling diminishes PKC inhibitor sensitivity in uveal melanoma” 🔵 Outstanding research led by Helen Rizos has been featured in #Oncogenesis. ▶️ Read the full open access article here: www.nature.com/articles/s41...

Check how this work provides evidence that targeting mitochondrial PE synthesis is sufficient to disrupt mitochondrial metabolism and promote oxidative stress, which may be a metabolic vulnerability that can be targeted to slow HCC progression.

“Targeting mitochondrial phosphatidylethanolamine alters mitochondrial metabolism and proliferation in hepatocellular carcinoma” 🔵 Timothy D. Heden‘s latest and impressive research is now available to read in #Oncogenesis. ▶️ Read the full open access article here: www.nature.com/articles/s41...

The authors demonstrated that B-lymphocyte kinase (BLK) inhibition targets the cancer stem cell (CSC) population. Combining conventional chemotherapy, which eliminates bulk tumor cells, with BLK inhibition could constitute a two-pronged therapeutic strategy that may improve patient survival.

“Transcriptomic analysis identifies B-lymphocyte kinase as a therapeutic target for desmoplastic small round cell tumor cancer stem cell-like cells” 🔵 Interesting research led by Sean B. Lee has been featured in #Oncogenesis. ▶️ Read the full open access article here: www.nature.com/articles/s41...

Check how this study shows that USP1 stabilizes HELLS through the deubiquitination pathway, promoting EMT and HRR-mediated chemotherapy resistance in HCC, offering a promising therapeutic strategy to suppress HCC progression and enhance the efficacy of FOLFOX-based chemotherapy.

“Dual roles of USP1 in HELLS deubiquitination and SUMOylation drive EMT and FOLFOX-based chemoresistance” 🔵 Wenjie Zheng’s latest research is now available to read in #Oncogenesis. ▶️ Read the full open access article here: www.nature.com/articles/s41...

Check how their findings provide TRIM1’s associations with clinical significance and demonstrate the novel oncogenic role of TRIM1 in CRC via activation of HIF1α signaling.

“An E3 ligase TRIM1 promotes colorectal cancer progression via K63-linked ubiquitination and activation of HIF1α” 🔵 Interesting research led by Kun Meng was featured in #Oncogenesis. ▶️ Read the full open access article here: www.nature.com/articles/s41...

Check how the authors were able to prevent tumor growth relapse from drug-tolerant persister (DTP) cells by inducing their eradication through strong oxidative stress and how it could be a promising avenue for treating pancreatic cancer in the clinic.

“Adaptation of redox metabolism in drug-tolerant persister cells is a vulnerability to prevent relapse in pancreatic cancer” 🔵 Alice Carrier’s latest and impressive research is now available to read in #Oncogenesis. ▶️ Read the full open access article here: www.nature.com/articles/s41...

Check how their results, revealing a strong positive correlation between PD-L1 expression and DDX3X, suggest the potential of DDX3X as a reliable marker for diagnosis and prognosis and treatment response prediction in pancreatic cancer.

“DDX3X interacts with SIRT7 to promote PD-L1 expression to facilitate PDAC progression” 🔵 Interesting research led by Xiaoping Zou was featured in #Oncogenesis. ▶️ Read the full open access article here: www.nature.com/articles/s41...

Check how their findings highlight ACSL6 as a critical determinant of docosahexaenoic acid (DHA) sensitivity in cancer, underscoring its potential as a predictive biomarker for chemotherapy–DHA combination strategies.

“ACSL6 modulates docosahexaenoic acid-induced cytotoxicity to potentiate chemotherapy response in colorectal and breast cancer” 🔵 Hui-Ping Hsu’s latest research is now available to read in #Oncogenesis. ▶️ Read the full open access article here: www.nature.com/articles/s41...

Check how their findings revealed that USP5 promotes HCC progression through deubiquitinating FASN, and targeting the USP5-FASN-PA axis could potentially serve as a strategic approach for the therapy of HCC.

“Stabilization of FASN by USP5-mediated deubiquitination promotes hepatocellular carcinoma progression” 🔵Chengrong Xie’s latest research is now available to read in #Oncogenesis. ▶️ Read the full open access article here: www.nature.com/articles/s41...

Happy Holidays and Best Wishes for 2026! As the year comes to an end, we would like to thank our readers, authors, reviewers, and the entire research community for their continued support and engagement with Oncogenesis. We wish you a joyful holiday season and a successful and inspiring New Year!

Check how their results provide experimental evidence to distinguish BCL2 transmembrane driver mutations from passenger mutations and provide new insight regarding selecting precision anti-tumor treatments.

“Phenotyping of cancer-associated somatic mutations in the BCL2 transmembrane domain” 🔵 Mar Orzáez’s fundamental research appeared in #Oncogenesis ▶️ Read the full open access article here: www.nature.com/articles/s41...

Check how overexpression of YTHDF3 in breast cancer cells upregulates the expression of ZEB1 and SMAD5, which promotes the EMT process, increasing the invasiveness of breast cancer cells. Take a closer look at the mechanism the authors propose.

“YTHDF3 promotes breast cancer osteolytic bone metastasis by enhancing the translation of ZEB1 and SMAD5” 🔵Wangjun Yan’s latest research is now available to read in #Oncogenesis. ▶️ Read the full open access article here: www.nature.com/articles/s41...

With that vision, I have joined Oncogenesis as an Associate Editor, committed to supporting a platform where impactful cancer research can flourish and inspire. Lab website: www.ssshen.com Delighted to have him on our team at Oncogenesis! 🤝

Science advances not only through discovery, but through dialogue—rigorous, transparent, and meaningful exchange across disciplines and borders. As the pace of innovation accelerates, so too must our responsibility to uphold the standards that give research its lasting value.

By uncovering the biology of drug-tolerant persister cells, we aim to shift the therapeutic lens from simply targeting bulk tumor populations to confronting the elusive reservoirs of relapse.

We focus on how melanoma and small cell lung carcinoma escape standard-of-care therapies through non-genetic, reversible states of persistence.

🧬 Meet One of Our Associate Editors: Shensi Shen @seansi.bsky.social As an Associate Professor and head of the Cancer Cell Plasticity Laboratory at the Institute of Thoracic Oncology, West China Hospital of Sichuan University, Chengdu, my research delves into the adaptive resilience of cancer.

Check how ACSL6, by modulating key metabolic and signaling pathways, could influence cellular susceptibility to ferroptosis and may guide therapeutic approaches that enhance chemotherapy through DHA supplementation.